Mind Medicine Inc (NAS:MNMD)
$ 8.19 -0.78 (-8.7%) Market Cap: 600.59 Mil Enterprise Value: 438.17 Mil PE Ratio: 0 PB Ratio: 2.93 GF Score: 41/100

Mind Medicine (MindMed) Inc at ROTH Conference Transcript

Mar 13, 2023 / 09:30PM GMT
Release Date Price: $3.03 (+0.66%)
Jonathan Aschoff
ROTH Capital Partners, LLC - Analyst

And with me now is the CEO of MindMed, Rob Barrow. Welcome, Rob. Nice to have you.

Questions & Answers

Jonathan Aschoff
ROTH Capital Partners, LLC - Analyst

So regarding the relatively potent hallucinogens as potential commercial drugs, can you describe the regulatory environment both here and in Europe for a fairly new class of drugs that can take people in different directions?

Rob Barrow;MindMed;Inc.;CEO;Board Director
Mind Medicine

()-&

Absolutely. Thanks so much for having us here in the conference. So for anyone who is not deeply acquainted with Mind Medicine, we're developing a portfolio of molecules for a variety of brain health disorders, the furthest along of which is a proprietary form of LSD, which we're developing for generalized anxiety disorder, Phase 2b study this year.

We're also developing other models by using these molecules, including a sub-perceptual,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot